Transgene Appoints Gaëlle Stadtler as Director of Human Resources
14 Gennaio 2021 - 6:00PM
Business Wire
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that
designs and develops virus-based immunotherapeutics against cancer,
today announces the appointment of Gaëlle Stadtler as Director of
Human Resources. Gaëlle is joining the Executive Committee and will
directly report to Hedi Ben Brahim, Chairman and CEO of
Transgene.
Commenting on this appointment, Hedi Ben Brahim said:
“Given therapeutic innovation is a globally competitive endeavor,
it is critical that Transgene continues to have access to highly
skilled and committed employees capable of designing novel
immunotherapies that can significantly improve the treatment of
solid tumors. In her new role as Director of Human Resources,
Gaëlle Stadtler’s mission is to continue developing the skills of
our 150 employees, to attract and retain talent and to support an
innovative corporate culture that is central to our success.”
Transgene’s Management Committee is comprised of the following
members:
- Hedi Ben Brahim, Chairman & Chief Executive Officer (CEO);
- Éric Quéméneur, Executive Vice-President, Chief Scientific
Officer (CSO); - Christophe Ancel, Vice-President Pharmaceutical
Operations & Qualified Pharmacist; - Maud Brandely-Talbot,
Vice-President Medical Affairs, Chief Medical Affairs (CMO); -
Jean-Philippe Del, Vice-President Chief Finance Officer (CFO); -
Thibaut du Fayet, Vice-President Corporate Development; - John
Felitti, Vice-President, General Counsel, Corporate Secretary; -
Gaëlle Stadtler, Vice-President Human Resources Director.
BIOGRAPHY Gaëlle Stadtler joined Transgene as Head of
Human Resources and Internal Communications in 2018. Between 2011
and 2017, Gaëlle held the positions of Human Resources Manager at
Sensient Flavors, and HR Generalist at L&L Products. She
started her career at Mars Inc. as a Talent and Learning &
Developement Coordinator. Gaëlle holds a master’s degree in
Management from Skema Business School Lille and a Master 2 HR from
EM Strasbourg.
About Transgene Transgene (Euronext: TNG) is a
biotechnology company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells. The Company’s clinical-stage
programs consist of two therapeutic vaccines (TG4001 for the
treatment of HPV-positive cancers, and TG4050, the first
individualized therapeutic vaccine based on the myvac® platform) as
well as two oncolytic viruses (TG6002 for the treatment of solid
tumors, and BT-001, the first oncolytic virus based on the
Invir.IO™ platform). With Transgene’s myvac® platform, therapeutic
vaccination enters the field of precision medicine with a novel
immunotherapy that is fully tailored to each individual. The myvac®
approach allows the generation of a virus-based immunotherapy that
encodes patient-specific mutations identified and selected by
Artificial Intelligence capabilities provided by its partner NEC.
With its proprietary platform Invir.IO™, Transgene is building on
its viral vector engineering expertise to design a new generation
of multifunctional oncolytic viruses. Transgene has an ongoing
Invir.IO™ collaboration with AstraZeneca. Additional information
about Transgene is available at: www.transgene.fr. Follow us on
Twitter: @TransgeneSA
Disclaimer This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210114005800/en/
Transgene: Lucie Larguier Director Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media: Citigate Dewe Rogerson David Dible/Sylvie
Berrebi + 44 (0)20 7638 9571
transgene@citigatedewerogerson.com
Grafico Azioni Transgene (EU:TNG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Transgene (EU:TNG)
Storico
Da Apr 2023 a Apr 2024